We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

SPIR:NYSESpire Global, Inc. Analysis

Data as of 2026-06-22 - not real-time

$18.85

Latest Price

8/10Risk

Risk Level: High

Executive Summary

The stock is trading above its short‑term moving averages, with the 20‑day SMA above the 50‑day SMA, signaling a bullish alignment. The MACD has turned negative, and the histogram remains below zero, suggesting weakening momentum. RSI sits near the midpoint, indicating no clear overbought or oversold condition. Price sits comfortably above the identified support level and well below the recent high resistance, giving a modest upside buffer. Volatility is exceptionally high, with a 30‑day swing exceeding one hundred percent, and beta is markedly above market, underscoring sensitivity to market moves. The recent large exercise of stock options by the CEO may increase dilution pressure.
However, the company’s fundamentals show negative operating margins and cash flow, while the DCF fair value is far below the current market price. Yet the trailing PE is well under the industry average, and the forward PE is negative, reflecting earnings uncertainty. Market sentiment is at extreme greed, which can fuel short‑term price lifts but also raise the risk of a sharp correction. Given the mix of bullish technical signals and weak fundamentals, the outlook is mixed. Investors should weigh the upside potential against the pronounced valuation and execution risks. A cautious stance is advisable until earnings trends improve.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • Bullish price above short‑term averages
  • Negative MACD momentum
  • High short‑term volatility

Medium Term

1–3 years
Cautious
Model confidence: 7/10

Key Factors

  • DCF fair value far below market price
  • Negative operating and free cash flow
  • Elevated beta and drawdown risk

Long Term

> 3 years
Cautious
Model confidence: 8/10

Key Factors

  • Sustained overvaluation relative to intrinsic value
  • Weak profitability metrics and earnings uncertainty
  • Potential dilution from recent option exercise

Key Metrics & Analysis

Financial Health

Revenue Growth-33.70%
Profit Margin77.12%
P/E Ratio11.9
ROE101.23%
ROA-27.19%
Debt/Equity12.90
P/B Ratio5.5
Op. Cash Flow$-77611000
Free Cash Flow$10.0M
Industry P/E31.4

Technical Analysis

TrendBullish
RSI50.2
Support$15.30
Resistance$25.93
MA 20$19.74
MA 50$19.05
MA 200$12.62
MACDBearish
VolumeStable
Fear & Greed Index91.43

Valuation

Fair Value$4.37
Target Price$20.88
Upside/Downside10.74%
GradeOvervalued
TypeValue

Risk Assessment

Beta3.59
Volatility124.67%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.